HairClone will be available in some UK Clinics in "early 2022" - Paul Kemp, HairClone CEO

pegasus2

Senior Member
My Regimen
Reaction score
5,143
that's the solution, but stemson and tsuji might get the hair back bald, what will replicell or hairclone do?
The target customer is not the 3 percent that are completely bald, so I don't know why we're talking about them
 

froggy7

Experienced Member
My Regimen
Reaction score
207
The target customer is not the 3 percent that are completely bald, so I don't know why we're talking about them
so treatment of stemson and tsuji may be redundant in the future, since there will be effective prevention methods
 

RolfLeeBuckler

Established Member
My Regimen
Reaction score
973
stemson and tsuji can give us dream hair - color, thickness, density, what will hairclone give us?

Unfortunately tsuji and stemson cant give us anything because they are to stupid and always talking sh*t. They will never success with a working product but they jerk off sitting in hairloss congresses and begin in scientific papers. They failed terribly and arent more than a dream unfortunately.

I see a little chance in HopeMedicine to success for the real cure - they are legit and financial good stabilized and devellopped a nice product of Bayer AG
 

froggy7

Experienced Member
My Regimen
Reaction score
207
Unfortunately tsuji and stemson cant give us anything because they are to stupid and always talking sh*t. They will never success with a working product but they jerk off sitting in hairloss congresses and begin in scientific papers. They failed terribly and arent more than a dream unfortunately.

I see a little chance in HopeMedicine to success for the real cure - they are legit and financial good stabilized and devellopped a nice product of Bayer AG
now is still fifty - fifty
 

scientist_0005

Banned
My Regimen
Reaction score
122
they have zero proof this actually works

and if they really solved the culturing problem why would stemson use IPCs which is a lot harder and more expensive if they could just culture them this way and maintain inductivity.

what hairclone is doing is very trivial compared to the other companies but there is also no clear proof of concept. its also quite different from replicel
 

pegasus2

Senior Member
My Regimen
Reaction score
5,143
This isnt guaranteed at all.
They had poor success rate, only 50 %
of responders in Aderans trial back then
That's ok. That's higher than minoxidil and it has no side effects. It will also work better than it did then. I really can't understand the complains. Don't evaluate it on what you wish it was. Just be happy that there is another ootion available next year. Would you rather they didn't release it because they can't give everyone perfect hair?

Stemson is aiming for full restoration. Their IPS method is more expensive and more effective than culturing and injecting dp cells. It's also not going to be ready in 2022,but this will, and I'll be in the UK getting it.
 

froggy7

Experienced Member
My Regimen
Reaction score
207
That's ok. That's higher than minoxidil and it has no side effects. It will also work better than it did then. I really can't understand the complains. Don't evaluate it on what you wish it was. Just be happy that there is another ootion available next year. Would you rather they didn't release it because they can't give everyone perfect hair?
100% true
 

Super Metroid

Established Member
My Regimen
Reaction score
164
Aderans did not decide not to continue it, they went bankrupt due to the financial crisis. Let's just say we totally disagree on every point
If this is a typical response it would be worth it. Do we know that however? It could be like werefckd said, this is the top 1% responder who secretly was on minoxidil as well.

And how about the safety profile?
 

soull

Established Member
My Regimen
Reaction score
372

LATEST CLINICAL TRIALS UPDATE RELEASED ON MARCH 26TH, 2009:​

A Phase II study, which was conducted by Dr Bessam Farjo in Manchester, is now complete.

This trial was designed to examine the effect of different DP delivery techniques and methods to ensure that the epidermal cells were in the correct state to respond to the signals and produce new hairs.

In this study, subjects were injected 900 times with 1µl aliquots of DP cells in a large area, which was photographed at the end of the study. Subjects were also injected in a smaller area, divided into two sections – counts were obtained by shaving and photographing the two small sections of scalp, injecting them multiple times (either one injection of 50 µl or 50 injections of 1 µl) with living DP cell suspension and then applying a specialised image analysis system to provide a total hair count. In these small sections, all 19 subjects in the trial were treated using a range of injection and scalp pre-stimulation techniques; the first six subjects were injected without stimulation of the scalp. In the remaining 13 subjects, the resident hair producing (epithelial) cells were stimulated at the time of delivery of the DP cells in one of the two treatment sites.

Thirteen subjects completed the 48-week trial with six subjects lost to follow-up. Of the 13 subjects completing the trial the data showed that:

  • 65% (11/17) of the treated sites in the non-stimulated group responded to the treatment by increasing numbers of hairs of all sizes.
  • 71% (12/17) of the treated sites in the non-stimulated group responded to the treatment by increasing numbers of hairs over 30 micron in diameter.
  • 78% (7/9) of the treated sites in the stimulated group responded to the treatment by increasing numbers of hairs of all sizes.
  • 100% (9/9) of the treated sites in the stimulated group responded to the treatment by increasing numbers of hairs over 30 micron in diameter.
The overall take rate (number of hairs produced per 100 injections) in the stimulated areas was:

  • 40% (n=6) for hairs of all sizes
  • 18% (n=6) for hairs over 30 micron in diameter
The larger (900 injection) area photographs have not yet been analysed.

This data is consistent with the interim data reported last September and further confirms the hypothesis that new hair production is improved by pre-stimulation of the scalp, leading to an interaction between the injected cells and the resident hair-producing cells.



Dr Bessam Farjo, the principal investigator for this study, said “We have learned a lot from this trial, including the different ways in which these cells can be delivered and that it is possible to do 1000 of these injections in a relatively short period of time and with little discomfort to the patient. I am very encouraged by this data both in the increase in the total number of hairs in the treated site, but more importantly by the increase in thicker hairs, those over 30 micron.”

More information is also published on www.intercytex.com
 

jan_miezda

Banned
My Regimen
Reaction score
291

LATEST CLINICAL TRIALS UPDATE RELEASED ON MARCH 26TH, 2009:​

A Phase II study, which was conducted by Dr Bessam Farjo in Manchester, is now complete.

This trial was designed to examine the effect of different DP delivery techniques and methods to ensure that the epidermal cells were in the correct state to respond to the signals and produce new hairs.

In this study, subjects were injected 900 times with 1µl aliquots of DP cells in a large area, which was photographed at the end of the study. Subjects were also injected in a smaller area, divided into two sections – counts were obtained by shaving and photographing the two small sections of scalp, injecting them multiple times (either one injection of 50 µl or 50 injections of 1 µl) with living DP cell suspension and then applying a specialised image analysis system to provide a total hair count. In these small sections, all 19 subjects in the trial were treated using a range of injection and scalp pre-stimulation techniques; the first six subjects were injected without stimulation of the scalp. In the remaining 13 subjects, the resident hair producing (epithelial) cells were stimulated at the time of delivery of the DP cells in one of the two treatment sites.

Thirteen subjects completed the 48-week trial with six subjects lost to follow-up. Of the 13 subjects completing the trial the data showed that:

  • 65% (11/17) of the treated sites in the non-stimulated group responded to the treatment by increasing numbers of hairs of all sizes.
  • 71% (12/17) of the treated sites in the non-stimulated group responded to the treatment by increasing numbers of hairs over 30 micron in diameter.
  • 78% (7/9) of the treated sites in the stimulated group responded to the treatment by increasing numbers of hairs of all sizes.
  • 100% (9/9) of the treated sites in the stimulated group responded to the treatment by increasing numbers of hairs over 30 micron in diameter.
The overall take rate (number of hairs produced per 100 injections) in the stimulated areas was:

  • 40% (n=6) for hairs of all sizes
  • 18% (n=6) for hairs over 30 micron in diameter
The larger (900 injection) area photographs have not yet been analysed.

This data is consistent with the interim data reported last September and further confirms the hypothesis that new hair production is improved by pre-stimulation of the scalp, leading to an interaction between the injected cells and the resident hair-producing cells.



Dr Bessam Farjo, the principal investigator for this study, said “We have learned a lot from this trial, including the different ways in which these cells can be delivered and that it is possible to do 1000 of these injections in a relatively short period of time and with little discomfort to the patient. I am very encouraged by this data both in the increase in the total number of hairs in the treated site, but more importantly by the increase in thicker hairs, those over 30 micron.”

More information is also published on www.intercytex.com
When hope was alive in 2009
 

pegasus2

Senior Member
My Regimen
Reaction score
5,143
If this is a typical response it would be worth it. Do we know that however? It could be like werefckd said, this is the top 1% responder who secretly was on minoxidil as well.

And how about the safety profile?
Why is everyone missing the fact that they've improved the procedure since then. This might be the worst result now.
 

scientist_0005

Banned
My Regimen
Reaction score
122
Why is everyone missing the fact that they've improved the procedure since then. This might be the worst result now.
indeed, in 2009 it was a total mystery how one would clone DP cells without them losing their inductive properties. only in 2013 was research published by Higgins about the spherical culturing method- before then, they where basically just mindlessly injecting cells that do not even function as native DP cells anymore
 
Top